Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001705 · ClinicalTrials.gov registry record · Phase 2
Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
NCT00001705: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00001705 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 141 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001705, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
Study Summary
Patients with metastatic melanoma who are HLA-A201+ will be immunized with a modified peptide from the gp100 molecule that contains a signal sequence designed to improve peptide presentation by antigen presenting cells. This peptide called gp100:ES209-217 (210M) will be administered either alone or in combination with high or low dose IL-2. Patients will be evaluated for clinical response, as well as undergo studies of the immunologic response to the peptide immunization.
Interventions
- DRUG IL-2
- DRUG GP100 peptide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 1998-07 |
| Est. Completion | 2001-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001705
The ClinicalTrials.gov registry entry for NCT00001705 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IL-2 is the first listed.
NCT00001705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001705 about?
NCT00001705 is a clinical study titled "Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence". Patients with metastatic melanoma who are HLA-A201+ will be immunized with a modified peptide from the gp100 molecule that contains a signal sequence designed to improve peptide presentation by antigen presenting cells. This peptide called gp100:ES209-217 (210M) will be administered either alone or ...
What is the current status of trial NCT00001705?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 1998-07. Estimated completion is 2001-06.
What interventions are being tested in trial NCT00001705?
The interventions under investigation include: IL-2 (DRUG), GP100 peptide (DRUG).
Who is sponsoring clinical trial NCT00001705?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.